A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
Public ClinicalTrials.gov record NCT02093923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
Study identification
- NCT ID
- NCT02093923
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2014 (Actual)
- Primary completion
- May 18, 2015 (Actual)
- Completion
- May 18, 2015 (Actual)
- Last update posted
- May 27, 2021
2014 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Health System - La Jolla | San Diego | California | 92122 | — |
| Allergy & Asthma Clinical Research | Walnut Creek | California | 94598 | — |
| University of South Florida Asthma, Allergy or Immunology Clinical Research Unit | Tampa | Florida | 33613 | — |
| Institute for Asthma & Allergy, PC | Chevy Chase | Maryland | 20815 | — |
| Massachusetts General Hospital Allergy Associates | Boston | Massachusetts | 02114 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Winthrop-University Hospital, Clinical Trials Center | Mineola | New York | 11501 | — |
| Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center | New York | New York | 10029 | — |
| UC Physicians Company | Cincinnati | Ohio | 45267 | — |
| Baker Allergy, Asthma and Dermatology Research Center | Lake Oswego | Oregon | 97035 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| AARA Research Center | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02093923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2021 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02093923 live on ClinicalTrials.gov.